20/20 Biolabs, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Jonathan Cohen (CEO) and Alan Bergman (CFO) certified the Q2 2026 Form 10-Q filed August 14, 2026, stating that financial statements fairly present the company's condition and results, and that disclosure controls and internal controls over financial reporting are effectively designed and maintained. No specific dollar amounts, transactions, or material changes are disclosed in these certification exhibits.
Why this rating
Boilerplate Sarbanes-Oxley certifications; standard periodic disclosure with no substantive business event or material transaction disclosed.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.